Semen Quality in Transgender Individuals Seeking Fertility Preservation
Andrology · 2026
DOI: 10.1111/andr.70268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Andrology, 2026. Verfasst von Maurizio De Rocco Ponce und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fundación Puigvert, Servicio De Andrología Fundació Puigvert - IRSantPau, Barcelona, Spain. Hauptthemen laut MEDLINE: Fertility Preservation, Transgender Persons, Semen Analysis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transgender individuals assigned male at birth (AMAB) may choose to preserve their fertility prior to starting gender‐affirming hormone therapy (GAHT). However, limited data exist regarding the baseline reproductive and hormonal characteristics of this population before and after GAHT.
Objectives
To characterize semen quality and hormonal profiles in transgender AMAB individuals prior to GAHT and compare findings with cisgender men and with transgender individuals who discontinued GAHT for at least 3 months. Materials and Methods This retrospective study included transgender AMAB individuals from two tertiary andrology centers who underwent sperm cryopreservation before GAHT initiation (treatment‐naïve group). Clinical evaluation included anthropometric measures, testicular volume assessment, varicocele detection, and sex hormone measures. Semen parameters were analyzed according to WHO criteria and compared with those of cisgender men and previously treated transgender individuals.
Results
Thirty‐two treatment‐naïve transgender AMAB individuals were included. Hormonal parameters were generally within reference ranges. Only 46.9% of treatment‐naïve individuals met WHO criteria for normozoospermia, compared with 75.5% of cisgender controls. Compared with nine previously treated individuals, estradiol levels were higher and seminal volume lower. A higher frequency of seminal abnormalities was observed, although not statistically significant.
Conclusions
A substantial proportion of treatment‐naïve transgender AMAB individuals exhibited impaired semen parameters prior to GAHT initiation. Prior GAHT exposure showed a trend toward poorer semen quality. These findings support early fertility counseling and preservation in transgender individuals prior to GAHT initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fundación Puigvert, Servicio De Andrología Fundació Puigvert - IRSantPau, Barcelona, Spain.
- Department of Medicine, University of Padua, Padua, Italy.
- Department of Systems Medicine, Unit of Andrology and Reproductive Medicine, University Hospital of Padua, Padua, Italy.
- Regional Reference Center for Gender Incongruence of the Veneto Region, University Hospital of Padua, Padua, Italy.
- Division of Experimental Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
- University Vita-Salute San Raffaele, Milan, Italy.
ORCID-Profile: Maurizio De Rocco Ponce, Alberto Ferlin
Zitieren
APA
Ponce, M. R., Troka, E., Raffo, M., Caballero, L. M. M., Ferlin, A., Salonia, A., Castañé, E. R., Scala, A., Garolla, A., & Gender Incongruence Interdisciplinary Group (GIIG) (2026). Semen Quality in Transgender Individuals Seeking Fertility Preservation. Andrology. https://doi.org/10.1111/andr.70268
Vancouver
Ponce MR, Troka E, Raffo M, Caballero LMM, Ferlin A, Salonia A, et al. Semen Quality in Transgender Individuals Seeking Fertility Preservation. Andrology. 2026. doi:10.1111/andr.70268
BibTeX
@article{Ponce2026,
author = {Ponce, Maurizio De Rocco and Troka, Eden and Raffo, Massimiliano and Caballero, Luis Miguel Malca and Ferlin, Alberto and Salonia, Andrea and Castañé, Eduard Ruiz and Scala, Alberto and Garolla, Andrea and Gender Incongruence Interdisciplinary Group (GIIG), Gender Incongruence Interdisciplinary Group (GIIG)},
title = {Semen Quality in Transgender Individuals Seeking Fertility Preservation},
journal = {Andrology},
year = {2026},
doi = {10.1111/andr.70268}
}
EUVIMED